About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

AscellaHealth Releases Q1 2025 Specialty & Rare Pipeline Digest™ Providing Essential Clinical Drug Updates

PipelineDigest_2025Q1_MAR-190-031425.3_Page_01

BERWYN, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today unveiled its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive digital resource for information on new, pending and upcoming specialty and rare disease drug launches and approvals, biosimilars and cell and gene therapies (CGTs). As the intricate specialty pharmaceutical landscape evolves with emerging therapies, this complimentary quarterly publication equips stakeholders with vital, timely updates into specialty product pipelines.

"The steady pace of FDA approvals for novel therapies and shifts in treatment approaches, especially in the specialty and orphan drug areas, highlight the demand for these timely, actionable insights to advance treatment options for complex and rare conditions,” says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth. “Developed by our talented and dedicated team of clinical researchers and analytics experts, this robust publication empowers manufacturers, payers and providers with the knowledge to strategically navigate this dynamic landscape, supporting our commitment to enhancing patient access to treatment and product affordability."

A Look Back: 2024
In 2024, the FDA approved 50 novel drugs, slightly fewer than the 55 approved in 2023, but still above the 10-year average of 47 approvals annually. Over half of these new drugs target rare or orphan diseases. Furthermore, 66% of the approvals were fast-tracked through at least one of the FDA's expedited programs designed to address serious health conditions, with 16% receiving accelerated approval, reflecting a continued drive for innovation in patient care and the potential to enhance public health.

Projected Trends: 2025-2026
Projections for 2025–2026 indicate that trends will remain similar to those of 2024–2025, despite the introduction of several high-cost treatments for rare diseases. Specialty drugs are expected to continue growing as a significant portion of overall drug spending, with these medications accounting for more than half of total drug expenditures in 2025-2026 and beyond.

Growth in Specialty and Orphan Drug Approvals:
The FDA’s focus on specialty medications and orphan drugs continues to expand, with 71% of recent submissions being for specialty medications and 34% for orphan drugs. This trend reflects a growing commitment to addressing complex and rare conditions through innovative treatments.

Read more findings in the latest Specialty & Rare Pipeline Digest™ here.

About AscellaHealth LLC
AscellaHealth is a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions. A dedicated team gets critical healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharma. Visit www.AscellaHealth.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9f14bad2-92c2-429a-b11e-d33acd247fe7

This press release was published by a CLEAR® Verified individual.


Media:
Nicole Dufour
CPR Communications
ndufour@cpronline.com
201.641.1911 x 54

Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.